All Updates

All Updates

icon
Filter
Funding
Tenaya Therapeutics plans USD 75 million in public offering
Precision Medicine
Nov 16, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Precision Medicine

Precision Medicine

Nov 16, 2022

Tenaya Therapeutics plans USD 75 million in public offering

Funding

  • Biotechnology company Tenaya Therapeutics has announced its plans to raise USD 75 million consisting of 22.6 million common shares at USD 2.6 per share via an underwritten public offering and it is offering pre-funded warrants as an alternative to common stock to purchase up to 6.2 million shares at USD 0.001 lower than the public offering price. The firm will also offer a 30-day option to purchase an additional up to 4,327,500 in common shares at the public offering price. The firm’s share price rose 8.8% to close at USD 3.19 on the 16th of November. 

  • Moreover, joint book-running managers of the offering include Morgan Stanley and Piper Sandler while co-lead managers for the offering will be H.C. Wainwright & Co. and Chardan. 

  • The new funds along with its existing cash balance will be used towards advancing its lead products, TN-201 (MYBPC3 gene therapy), TN-301 (HDAC6i small molecule), and TN-401 (PKP2 gene therapy) towards clinical and preclinical stages. In addition, the funds will be used to develop early research programs, improve its platform, for operations, and working capital and corporate expenses.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.